← All trials
NCT04405960
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2017
- Primary completion
- Sep 30, 2017
- Completion date
- Dec 31, 2017
- First posted
- May 28, 2020
- Last posted
- May 28, 2020
- Enrollment
- 146
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Syarif Hidayatullah State Islamic UniversityLead sponsor
- Syarif Hidayatullah State Islamic UniversityOverall official - principal investigator
- Syarif Hidayatullah State Islamic UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.